The role of PPARβ/δ in the management of metabolic syndrome and its associated cardiovascular complications

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 11, Issue 4, 2011, Pages 273-284

  Benetti, Elisa ^a   Patel, Nimesh S A ^b   Collino, Massimo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cardiovascular disease; Metabolic syndrome; Peroxisome proliferators activated receptors; PPAR

Indexed keywords

2 [4 [2 [3 (2,4 DIFLUOROPHENYL) 1 HEPTYLUREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 3 CHLORO 4 [3 (7 PROPYL 3 TRIFLUOROMETHYLBENZISOXAZOL 6 YLOXY)PROPYLTHIO]PHENYLACETIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; FIBRIC ACID DERIVATIVE; GLUCOSE; GSK 0660; GW 2433; HETERODIMER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; L 165031; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID;

ARTICLE; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DNA SEQUENCE; DYSLIPIDEMIA; FATTY ACID METABOLISM; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC REGULATION; METABOLIC SYNDROME X; NONHUMAN; PROTEIN DNA BINDING; TRANSCRIPTION REGULATION;

EID: 80055111435     PISSN: 18715303     EISSN: 18715303     Source Type: Journal    
DOI: 10.2174/187153011797881175     Document Type: Article

References (121)

1. Greene, M.E.; Blumberg, B.; McBride, O.W.; Yi, H.F.; Kronquist, K.; Kwan, K.; Hsieh, L.; Greene, G. and Nimer, S.D. (1995) Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr., 4, 281-299.
2. Sher, T.; Yi, H.F.; McBride, O.W. and Gonzalez, F.J. (1993) cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry, 32, 5598-5604.
3. Yoshikawa, T.; Brkanac, Z.; Dupont, B.R.; Xing, G.Q.; Leach, R.J. and Detera-Wadleigh, S.D. (1996) Assignment of the human nuclear hormone receptor, NUC1 (PPARD), to chromosome 6p21.1-p21.2. Genomics, 35, 637-638.
4. Issemann, I. and Green, S. (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 347, 645-650.
5. Desvergne, B. and Wahli, W. (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 20, 649-688.
6. Vamecq, J. and Draye, J.P. (1989) Pathophysiology of peroxisomal beta-oxidation. Essays Biochem., 24, 115-225.
7. Gurnell, M. (2003) PPARgamma and metabolism: insights from the study of human genetic variants. Clin. Endocrinol. (Oxf), 59, 267-277.
8. Schmidt, A.; Endo, N.; Rutledge, S.J.; Vogel, R.; Shinar, D. and Rodan, G.A. (1992) Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol., 6, 1634-1641.
9. Amri, E.Z.; Bonino, F.; Ailhaud, G.; Abumrad, N.A. and Grimaldi, P.A. (1995) Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors. J. Biol. Chem., 270, 2367-2371.
10. Hu, E.; Kim, J.B.; Sarraf, P. and Spiegelman, B.M. (1996) Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science, 274, 2100-2103.
11. Schwabe, J.W.; Neuhaus, D. and Rhodes, D. (1990) Solution structure of the DNA-binding domain of the oestrogen receptor. Nature, 348, 458-461.
12. Fajas, L.; Auboeuf, D.; Raspe, E.; Schoonjans, K.; Lefebvre, A.M.; Saladin, R.; Najib, J.; Laville, M.; Fruchart, J.C.; Deeb, S.; Vidal-Puig, A.; Flier, J.; Briggs, M.R.; Staels, B.; Vidal, H. and Auwerx, J. (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem., 272, 18779-18789.
13. Onate, S.A.; Tsai, S.Y.; Tsai, M.J. and O'Malley, B.W. (1995) Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science, 270, 1354-1357.
14. Lefebvre, P.; Chinetti, G.; Fruchart, J.C. and Staels, B. (2006) Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J. Clin. Invest., 116, 571-580.
15. Kersten, S.; Seydoux, J.; Peters, J.M.; Gonzalez, F.J.; Desvergne, B. and Wahli, W. (1999) Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest., 103, 1489-1498.
16. Chou, C.J.; Haluzik, M.; Gregory, C.; Dietz, K.R.; Vinson, C.; Gavrilova, O. and Reitman, M.L. (2002) WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J. Biol. Chem., 277, 24484-24489.
17. Kim, H.; Haluzik, M.; Asghar, Z.; Yau, D.; Joseph, J.W.; Fernandez, A.M.; Reitman, M.L.; Yakar, S.; Stannard, B.; Heron-Milhavet, L.; Wheeler, M.B. and LeRoith, D. (2003) Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes, 52, 1770-1778.
18. Feige, J.N.; Gelman, L.; Michalik, L.; Desvergne, B. and Wahli, W. (2006) From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res., 45, 120-159.
19. Rosen, E.D.; Sarraf, P.; Troy, A.E.; Bradwin, G.; Moore, K.; Milstone, D.S.; Spiegelman, B.M. and Mortensen, R.M. (1999) PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell., 4, 611-617.
20. Hevener, A.L.; He, W.; Barak, Y.; Le, J.; Bandyopadhyay, G.; Olson, P.; Wilkes, J.; Evans, R.M. and Olefsky, J. (2003) Muscle-specific Pparg deletion causes insulin resistance. Nat. Med., 9, 1491-1497.
21. Kliewer, S.A.; Forman, B.M.; Blumberg, B.; Ong, E.S.; Borgmeyer, U.; Mangelsdorf, D.J.; Umesono, K. and Evans, R.M. (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA, 91, 7355-7359.
22. Xu, H.E.; Lambert, M.H.; Montana, V.G.; Parks, D.J.; Blanchard, S.G.; Brown, P.J.; Sternbach, D.D.; Lehmann, J.M.; Wisely, G.B.; Willson, T.M.; Kliewer, S.A. and Milburn, M.V. (1999) Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell., 3, 397-403.
23. Theocharisa, S.; Margeli, A. and Kouraklis, G. (2003) Peroxisome proliferator activated receptor-gamma ligands as potent antineoplastic agents. Curr. Med. Chem. Anticancer Agents, 3, 239-251.
24. Willson, T.M.; Brown, P.J.; Sternbach, D.D. and Henke, B.R. (2000) The PPARs: from orphan receptors to drug discovery. J. Med. Chem., 43, 527-550.
25. Forman, B.M.; Chen, J. and Evans, R.M. (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. USA, 94, 4312-4317.
26. Suhara, W.; Koide, H.; Okuzawa, T.; Hayashi, D.; Hashimoto, T. and Kojo, H. (2009) Cow's milk increases the activities of human nuclear receptors peroxisome proliferator-activated receptors alpha and delta and retinoid X receptor alpha involved in the regulation of energy homeostasis, obesity, and inflammation. J. Dairy Sci., 92, 4180-4187.
27. Berger, J.; Leibowitz, M.D.; Doebber, T.W.; Elbrecht, A.; Zhang, B.; Zhou, G.; Biswas, C.; Cullinan, C.A.; Hayes, N.S.; Li, Y.; Tanen, M.; Ventre, J.; Wu, M.S.; Berger, G.D.; Mosley, R.; Marquis, R.; Santini, C.; Sahoo, S.P.; Tolman, R.L.; Smith, R.G. and Moller, D.E. (1999) Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J. Biol. Chem., 274, 6718-6725.
28. Lim, H. and Dey, S.K. (2000) PPAR delta functions as a prostacyclin receptor in blastocyst implantation. Trends Endocrinol. Metab., 11, 137-142.
29. Martens, F.M.; Visseren, F.L.; Lemay, J.; de Koning, E.J. and Rabelink, T.J. (2002) Metabolic and additional vascular effects of thiazolidinediones. Drugs, 62, 1463-1480.
30. Shearer, B.G.; Steger, D.J.; Way, J.M.; Stanley, T.B.; Lobe, D.C.; Grillot, D.A.; Iannone, M.A.; Lazar, M.A.; Willson, T.M. and Billin, A.N. (2008) Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist. Mol. Endocrinol., 22, 523-529.
31. Shi, Y.; Hon, M. and Evans, R.M. (2002) The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc. Natl. Acad. Sci USA, 99, 2613-2618.
32. Palmer, C.N.; Hsu, M.H.; Griffin, H.J. and Johnson, E.F. (1995) Novel sequence determinants in peroxisome proliferator signaling. J. Biol. Chem., 270, 16114-16121.
33. Juge-Aubry, C.; Pernin, A.; Favez, T.; Burger, A.G.; Wahli, W.; Meier, C.A. and Desvergne, B. (1997) DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5'-flanking region. J. Biol. Chem., 272, 25252-25259.
34. Pascual, G. and Glass, C.K. (2006) Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol. Metab., 17, 321-327.
35. Kodera, Y.; Takeyama, K.; Murayama, A.; Suzawa, M.; Masuhiro, Y. and Kato, S. (2000) Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J. Biol. Chem., 275, 33201-33204.
36. Chung, S.W.; Kang, B.Y.; Kim, S.H.; Pak, Y.K.; Cho, D.; Trinchieri, G. and Kim, T.S. (2000) Oxidized low density lipo-protein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J. Biol. Chem., 275, 32681-32687.
37. Ding, G.; Cheng, L.; Qin, Q.; Frontin, S. and Yang, Q. (2006) PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J. Mol. Cell. Cardiol., 40, 821-828.
38. Planavila, A.; Rodriguez-Calvo, R.; Jove, M.; Michalik, L.; Wahli, W.; Laguna, J.C. and Vazquez-Carrera, M. (2005) Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc. Res., 65, 832-841.
39. Kino, T.; Rice, K.C. and Chrousos, G.P. (2007) The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition. Eur. J. Clin. Invest., 37, 425-433.
40. Meissner, M.; Hrgovic, I.; Doll, M.; Naidenow, J.; Reichenbach, G.; Hailemariam-Jahn, T.; Michailidou, D.; Gille, J.; Kaufmann, R. (2010) Peroxisome proliferator-activated receptor {delta} activators induce IL-8 expression in nonstimulated endothelial cells in a transcriptional and posttranscriptional manner. J. Biol. Chem., 285, 33797-33804.
41. Jeong, A.Y.; Lee, M.Y.; Lee, S.H.; Park, J.H. and Han, H.J. (2009) PPARdelta agonist-mediated ROS stimulates mouse embryonic stem cell proliferation through cooperation of p38 MAPK and Wnt/beta-catenin. Cell Cycle, 8, 611-619.
42. Li, Y.; Cheng, L.; Qin, Q.; Liu, J.; Lo, W.K.; Brako, L.A. and Yang, Q. (2009) High-fat feeding in cardiomyocyte-restricted PPARdelta knockout mice leads to cardiac overexpression of lipid metabolic genes but fails to rescue cardiac phenotypes. J. Mol. Cell. Cardiol., 47, 536-543.
43. Lee, C.H.; Chawla, A.; Urbiztondo, N.; Liao, D.; Boisvert, W.A.; Evans, R.M. and Curtiss, L.K. (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science, 302, 453-457.
44. Dent, A.L.; Shaffer, A.L.; Yu, X.; Allman, D. and Staudt, L.M. (1997) Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science, 276, 589-592.
45. Dent, A.L.; Vasanwala, F.H. and Toney, L.M. (2002) Regulation of gene expression by the proto-oncogene BCL-6. Crit. Rev. Oncol. Hematol., 41, 1-9.
46. Igoillo-Esteve, M.; Gurzov, E.N.; Eizirik, D.L.; Cnop, M. The transcription factor B-cell lymphoma (BCL)-6 modulates pancreatic {beta}-cell inflammatory responses. Endocrinology, 152, 447-456.
47. Kumagai, T.; Miki, T.; Kikuchi, M.; Fukuda, T.; Miyasaka, N.; Kamiyama, R. and Hirosawa, S. (1999) The proto-oncogene Bc16 inhibits apoptotic cell death in differentiation-induced mouse myogenic cells. Oncogene, 18, 467-475.
48. Barish, G.D.; Atkins, A.R.; Downes, M.; Olson, P.; Chong, L.W.; Nelson, M.; Zou, Y.; Hwang, H.; Kang, H.; Curtiss, L.; Evans, R.M. and Lee, C.H. (2008) PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc. Natl. Acad. Sci. USA, 105, 4271-4276.
49. Takata, Y.; Liu, J.; Yin, F.; Collins, A.R.; Lyon, C.J.; Lee, C.H.; Atkins, A.R.; Downes, M.; Barish, G.D.; Evans, R.M.; Hsueh, W.A. and Tangirala, R.K. (2008) PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc. Natl. Acad. Sci. USA, 105, 4277-4282.
50. Ravaux, L.; Denoyelle, C.; Monne, C.; Limon, I.; Raymondjean, M. and El Hadri, K. (2007) Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the proto-oncogene BCL-6. Mol. Cell Biol., 27, 8374-8387.
51. Matsushita, Y.; Ogawa, D.; Wada, J.; Yamamoto, N.; Shikata, K.; Sato, C.; Tachibana, H.; Toyota, N. and Makino, H. (2011) Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice. Diabetes, 60, 960-968.
52. Tan, N.S.; Michalik, L.; Noy, N.; Yasmin, R.; Pacot, C.; Heim, M.; Fluhmann, B.; Desvergne, B. and Wahli, W. (2001) Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev., 15, 3263-3277.
53. Rieck, M.; Wedeken, L.; Muller-Brusselbach, S.; Meissner, W. and Muller, R. (2007) Expression level and agonist-binding affect the turnover, ubiquitination and complex formation of peroxisome proliferator activated receptor beta. FEBS J., 274, 5068-5076.
54. Krogsdam, A.M.; Nielsen, C.A.; Neve, S.; Holst, D.; Helledie, T.; Thomsen, B.; Bendixen, C.; Mandrup, S. and Kristiansen, K. (2002) Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated trans-activation. Biochem. J., 363, 157-165.
55. Choi, J.H.; Banks, A.S.; Estall, J.L.; Kajimura, S.; Bostrom, P.; Laznik, D.; Ruas, J.L.; Chalmers, M.J.; Kamenecka, T.M.; Bluher, M.; Griffin, P.R. and Spiegelman, B.M. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature, 466, 451-456.
56. Reaven, G.M. (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 37, 1595-1607.
57. (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 285, 2486-2497.
58. Alberti, K.G. and Zimmet, P.Z. (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med., 15, 539-553.
59. Grundy, S.M.; Brewer, H.B.Jr.; Cleeman, J.I.; Smith, S.C.Jr. and Lenfant, C. (2004) Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 109, 433-438.
60. Leibowitz, M.D.; Fievet, C.; Hennuyer, N.; Peinado-Onsurbe, J.; Duez, H.; Bergera, J.; Cullinan, C.A.; Sparrow, C.P.; Baffic, J.; Berger, G.D.; Santini, C.; Marquis, R.W.; Tolman, R.L.; Smith, R.G.; Moller, D.E. and Auwerx, J. (2000) Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett., 473, 333-336.
61. Oliver, W.R.Jr.; Shenk, J.L.; Snaith, M.R.; Russell, C.S.; Plunket, K.D.; Bodkin, N.L.; Lewis, M.C.; Winegar, D.A.; Sznaidman, M.L.; Lambert, M.H.; Xu, H.E.; Sternbach, D.D.; Kliewer, S.A.; Hansen, B.C. and Willson, T.M. (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA, 98, 5306-5311.
62. van der Veen, J.N.; Kruit, J.K.; Havinga, R.; Baller, J.F.; Chimini, G.; Lestavel, S.; Staels, B.; Groot, P.H.; Groen, A.K. and Kuipers, F. (2005) Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J. Lipid Res., 46, 526-534.
63. Tanaka, T.; Yamamoto, J.; Iwasaki, S.; Asaba, H.; Hamura, H.; Ikeda, Y.; Watanabe, M.; Magoori, K.; Ioka, R.X.; Tachibana, K.; Watanabe, Y.; Uchiyama, Y.; Sumi, K.; Iguchi, H.; Ito, S.; Doi, T.; Hamakubo, T.; Naito, M.; Auwerx, J.; Yanagisawa, M.; Kodama, T. and Sakai, J. (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. USA, 100, 15924-15929.
64. Wang, Y.X.; Lee, C.H.; Tiep, S.; Yu, R.T.; Ham, J.; Kang, H. and Evans, R.M. (2003) Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell, 113, 159-170.
65. Lee, C.H.; Olson, P.; Hevener, A.; Mehl, I.; Chong, L.W.; Olefsky, J.M.; Gonzalez, F.J.; Ham, J.; Kang, H.; Peters, J.M. and Evans, R.M. (2006) PPARdelta regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. USA, 103, 3444-3449.
66. Winzell, M.S.; Wulff, E.M.; Olsen, G.S.; Sauerberg, P.; Gotfredsen, C.F. and Ahren, B. Improved insulin sensitivity and islet function after PPARdelta activation in diabetic db/db mice. Eur. J. Pharmacol., 626, 297-305.
67. Barroso, E.; Rodriguez-Calvo, R.; Serrano-Marco, L.; Astudillo, A.M.; Balsinde, J.; Palomer, X. and Vazquez-Carrera, M. The PPAR{beta}/{delta} activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1{alpha}-Lipin 1-PPAR{alpha} pathway leading to increased fatty acid oxidation. Endocrinology, 152, 1848-1859.
68. Liu, S.; Hatano, B.; Zhao, M.; Yen, C.C.; Kang, K.; Reilly, S.M.; Gangl, M.R.; Gorgun, C.; Balschi, J.A.; Ntambi, J.M.; Lee, C.H. (2011) Role of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulation. J. Biol. Chem., 286, 1237-1247.
69. Ye, J.M.; Tid-Ang, J.; Turner, N.; Zeng, X.Y.; Li, H.Y.; Cooney, G.J.; Wulff, E.M.; Sauerberg, P. and Kraegen, E.W. PPARdelta agonists have opposing effects on insulin resistance in high fat-fed rats and mice due to different metabolic responses in muscle. Br. J. Pharmacol., 163, 556-566.
70. Chevillotte, E.; Rieusset, J.; Roques, M.; Desage, M. and Vidal, H. (2001) The regulation of uncoupling protein-2 gene expression by omega-6 polyunsaturated fatty acids in human skeletal muscle cells involves multiple pathways, including the nuclear receptor peroxisome proliferator-activated receptor beta. J. Biol. Chem., 276, 10853-10860.
71. Holst, D.; Luquet, S.; Nogueira, V.; Kristiansen, K.; Leverve, X. and Grimaldi, P.A. (2003) Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle. Biochim. Biophys. Acta, 1633, 43-50.
72. Son, C.; Hosoda, K.; Matsuda, J.; Fujikura, J.; Yonemitsu, S.; Iwakura, H.; Masuzaki, H.; Ogawa, Y.; Hayashi, T.; Itoh, H.; Nishimura, H.; Inoue, G.; Yoshimasa, Y.; Yamori, Y. and Nakao, K. (2001) Up-regulation of uncoupling protein 3 gene expression by fatty acids and agonists for PPARs in L6 myotubes. Endocrinology, 142, 4189-4194.
73. Luquet, S.; Lopez-Soriano, J.; Holst, D.; Fredenrich, A.; Melki, J.; Rassoulzadegan, M. and Grimaldi, P.A. (2003) Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J., 17, 2299-2301.
74. Wang, Y.X.; Zhang, C.L.; Yu, R.T.; Cho, H.K.; Nelson, M.C.; Bayuga-Ocampo, C.R.; Ham, J.; Kang, H. and Evans, R.M. (2004) Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol., 2, e294.
75. Schuler, M.; Ali, F.; Chambon, C.; Duteil, D.; Bornert, J.M.; Tardivel, A.; Desvergne, B.; Wahli, W.; Chambon, P. and Metzger, D. (2006) PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab., 4, 407-414.
76. Narkar, V.A.; Downes, M.; Yu, R.T.; Embler, E.; Wang, Y.X.; Banayo, E.; Mihaylova, M.M.; Nelson, M.C.; Zou, Y.; Juguilon, H.; Kang, H.; Shaw, R.J. and Evans, R.M. (2008) AMPK and PPARdelta agonists are exercise mimetics. Cell, 134, 405-415.
77. Thevis, M.; Moller, I.; Thomas, A.; Beuck, S.; Rodchenkov, G.; Bornatsch, W.; Geyer, H. and Schanzer, W. (2010) Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls. Anal. Bioanal. Chem., 396, 2479-2491.
78. Gami, A.S.; Witt, B.J.; Howard, D.E.; Erwin, P.J.; Gami, L.A.; Somers, V.K. and Montori, V.M. (2007) Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol., 49, 403-414.
79. Lakka, H.M.; Laaksonen, D.E.; Lakka, T.A.; Niskanen, L.K.; Kumpusalo, E.; Tuomilehto, J. and Salonen, J.T. (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 288, 2709-2716.
80. Isomaa, B.; Almgren, P.; Tuomi, T.; Forsen, B.; Lahti, K.; Nissen, M.; Taskinen, M.R. and Groop, L. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24, 683-689.
81. van der Heijden, A.A.; Ortegon, M.M.; Niessen, L.W.; Nijpels, G. and Dekker, J.M. (2009) Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study. Diabetes Care, 32, 2094-2098.
82. Wellen, K.E. and Hotamisligil, G.S. (2005) Inflammation, stress, and diabetes. J. Clin. Invest., 115, 1111-1119.
83. Hotamisligil, G.S.; Shargill, N.S. and Spiegelman, B.M. (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 259, 87-91.
84. Uysal, K.T.; Wiesbrock, S.M.; Marino, M.W. and Hotamisligil, G.S. (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature, 389, 610-614.
85. Krogh-Madsen, R.; Plomgaard, P.; Moller, K.; Mittendorfer, B. and Pedersen, B.K. (2006) Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am. J. Physiol. Endocrinol. Metab., 291, E108-114.
86. Ridker, P.M.; Buring, J.E.; Cook, N.R. and Rifai, N. (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation, 107, 391-397.
87. Piqueras, L.; Sanz, M.J.; Perretti, M.; Morcillo, E.; Norling, L.; Mitchell, J.A.; Li, Y. and Bishop-Bailey, D. (2009) Activation of PPAR{beta}/{delta} inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. J. Leukoc. Biol., 86, 115-22.
88. Collino, M.; Benetti, E.; Miglio, G.; Castiglia, S.; Rosa, A.C.; Aragno, M.; Thiemermann, C. and Fantozzi, R. Peroxisome proliferator-activated receptor beta/delta agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Radic. Biol. Med., 50, 345-353.
89. Di Paola, R.; Esposito, E.; Mazzon, E.; Paterniti, I.; Galuppo, M. and Cuzzocrea, S. (2010) GW0742, a selective PPAR-beta/delta agonist, contributes to the resolution of inflammation after gut ischemia/reperfusion injury. J. Leukoc. Biol., 88, 291-301.
90. Kapoor, A.; Collino, M.; Castiglia, S.; Fantozzi, R. and Thiemermann, C. Activation of peroxisome proliferator-activated receptor-beta/delta attenuates myocardial ischemia/reperfusion injury in the rat. Shock, 34, 117-124.
91. Letavernier, E.; Perez, J.; Joye, E.; Bellocq, A.; Fouqueray, B.; Haymann, J.P.; Heudes, D.; Wahli, W.; Desvergne, B. and Baud, L. (2005) Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J. Am. Soc. Nephrol., 16, 2395-2402.
92. Yue, T.L.; Nerurkar, S.S.; Bao, W.; Jucker, B.M.; Sarov-Blat, L.; Steplewski, K.; Ohlstein, E.H. and Willette, R.N. (2008) In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats. J. Pharmacol. Exp. Ther., 325, 466-474.
93. Yin, K.J.; Deng, Z.; Hamblin, M.; Zhang, J. and Chen, Y.E. (2011) Vascular PPAR{delta} Protects Against Stroke-Induced Brain Injury. Arterioscler. Thromb. Vasc. Biol., 31, 574-581.
94. Kapoor, A.; Shintani, Y.; Collino, M.; Osuchowski, M.F.; Busch, D.; Patel, N.S.; Sepodes, B.; Castiglia, S.; Fantozzi, R.; Bishop-Bailey, D.; Mota-Filipe, H.; Yaqoob, M.M.; Suzuki, K.; Bahrami, S.; Desvergne, B.; Mitchell, J.A. and Thiemermann, C. Protective role of peroxisome proliferator-activated receptor-beta/delta in septic shock. Am. J. Respir. Crit. Care Med., 182, 1506-1515.
95. Rodriguez-Calvo, R.; Serrano, L.; Coll, T.; Moullan, N.; Sanchez, R.M.; Merlos, M.; Palomer, X.; Laguna, J.C.; Michalik, L.; Wahli, W. and Vazquez-Carrera, M. (2008) Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopoly-saccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2. Diabetes, 57, 2149-2157.
96. Zingarelli, B.; Piraino, G.; Hake, P.W.; O'Connor, M.; Denenberg, A.; Fan, H. and Cook, J.A. (2010) Peroxisome proliferator-activated receptor {delta} regulates inflammation via NF-{kappa}B signaling in polymicrobial sepsis. Am. J. Pathol., 177, 1834-1847.
97. Alvarez-Guardia, D.; Palomer, X.; Coll, T.; Serrano, L.; Rodriguez-Calvo, R.; Davidson, M.M.; Merlos, M.; El Kochairi, I.; Michalik, L.; Wahli, W. and Vazquez-Carrera, M. (2011) PPARbeta/delta activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochim. Biophys. Acta, 1811, 59-67.
98. Rival, Y.; Beneteau, N.; Taillandier, T.; Pezet, M.; Dupont-Passelaigue, E.; Patoiseau, J.F.; Junquero, D.; Colpaert, F.C. and Delhon, A. (2002) PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur. J. Pharmacol., 435, 143-151.
99. Cheng, L.; Ding, G.; Qin, Q.; Huang, Y.; Lewis, W.; He, N.; Evans, R.M.; Schneider, M.D.; Brako, F.A.; Xiao, Y.; Chen, Y.E. and Yang, Q. (2004) Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med., 10, 1245-1250.
100. Cheng, L.; Ding, G.; Qin, Q.; Xiao, Y.; Woods, D.; Chen, Y.E. and Yang, Q. (2004) Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes. Biochem. Biophys. Res. Commun., 313, 277-286.
101. Wang, M.; Zhang, W.; Crisostomo, P.; Markel, T.; Meldrum, K.K.; Fu, X.Y. and Meldrum, D.R. (2007) Endothelial STAT3 plays a critical role in generalized myocardial proinflammatory and proapoptotic signaling. Am. J. Physiol. Heart Circ. Physiol., 293, H2101-2108.
102. Welte, T.; Zhang, S.S.; Wang, T.; Zhang, Z.; Hesslein, D.G.; Yin, Z.; Kano, A.; Iwamoto, Y.; Li, E.; Craft, J.E.; Bothwell, A.L.; Fikrig, E.; Koni, P.A.; Flavell, R.A. and Fu, X.Y. (2003) STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc. Natl. Acad. Sci. USA, 100, 1879-1884.
103. Ueki, K.; Kondo, T.; Tseng, Y.H. and Kahn, C.R. (2004) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. USA, 101, 10422-10427.
104. Farrell, G.C. (2005) Signalling links in the liver: knitting SOCS with fat and inflammation. J. Hepatol., 43, 193-196.
105. Collino, M.; Aragno, M.; Castiglia, S.; Miglio, G.; Tomasinelli, C.; Boccuzzi, G.; Thiemermann, C. and Fantozzi, R. Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br. J. Pharmacol., 160, 1892-1902.
106. Cantley, L.C. (2002) The phosphoinositide 3-kinase pathway. Science, 296, 1655-1657.
107. Matsui, T.; Tao, J.; del Monte, F.; Lee, K.H.; Li, L.; Picard, M.; Force, T.L.; Franke, T.F.; Hajjar, R.J. and Rosenzweig, A. (2001) Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation, 104, 330-335.
108. Cross, D.A.; Alessi, D.R.; Cohen, P.; Andjelkovich, M. and Hemmings, B.A. (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature, 378, 785-789.
109. Moule, S.K.; Welsh, G.I.; Edgell, N.J.; Foulstone, E.J.; Proud, C.G. Denton, R.M. (1997) Regulation of protein kinase B and glycogen synthase kinase-3 by insulin and beta-adrenergic agonists in rat epididymal fat cells. Activation of protein kinase B by wortmannin-sensitive and -insensitive mechanisms. J. Biol. Chem., 272, 7713-7719.
110. Collino, M.; Aragno, M.; Castiglia, S.; Tomasinelli, C.; Thiemermann, C.; Boccuzzi, G. and Fantozzi, R. (2009) Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta. Diabetes, 58, 235-242.
111. Collino, M.; Thiemermann, C.; Mastrocola, R.; Gallicchio, M.; Benetti, E.; Miglio, G.; Castiglia, S.; Danni, O.; Murch, O.; Dianzani, C.; Aragno, M. and Fantozzi, R. (2008) Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. Shock, 30, 299-307.
112. Hoeflich, K.P.; Luo, J.; Rubie, E.A.; Tsao, M.S.; Jin, O. and Woodgett, J.R. (2000) Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature, 406, 86-90.
113. Takada, Y.; Fang, X.; Jamaluddin, M.S.; Boyd, D.D. and Aggarwal, B.B. (2004) Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J. Biol. Chem., 279, 39541-39554.
114. Schwabe, R.F. and Brenner, D.A. (2002) Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol., 283, G204-211.
115. Di-Poi, N.; Tan, N.S.; Michalik, L.; Wahli, W. and Desvergne, B. (2002) Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol. Cell., 10, 721-733.
116. Jimenez, R.; Sanchez, M.; Zarzuelo, M.J.; Romero, M.; Quintela, A.M.; Lopez-Sepulveda, R.; Galindo, P.; Gomez-Guzman, M.; Haro, J.M.; Zarzuelo, A.; Perez-Vizcaino, F. and Duarte, J. Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor beta agonists via the phosphatidyl-inositol-3 kinase-Akt pathway. J. Pharmacol. Exp. Ther., 332, 554-561.
117. Han, J.K.; Lee, H.S.; Yang, H.M.; Hur, J.; Jun, S.I.; Kim, J.Y.; Cho, C.H.; Koh, G.Y.; Peters, J.M.; Park, K.W.; Cho, H.J.; Lee, H.Y.; Kang, H.J.; Oh, B.H.; Park, Y.B. and Kim, H.S. (2008) Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. Circulation, 118, 1021-1033.
118. Han, S.; Ritzenthaler, J.D.; Wingerd, B. and Roman, J. (2005) Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein beta. J. Biol. Chem., 280, 33240-33249.
119. Sprecher, D.L.; Massien, C.; Pearce, G.; Billin, A.N.; Perlstein, I.; Willson, T.M.; Hassall, D.G.; Ancellin, N.; Patterson, S.D.; Lobe, D.C. and Johnson, T.G. (2007) Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler. Thromb. Vasc. Biol., 27, 359-365.
120. Riserus, U.; Sprecher, D.; Johnson, T.; Olson, E.; Hirschberg, S.; Liu, A.; Fang, Z.; Hegde, P.; Richards, D.; Sarov-Blat, L.; Strum, J.C.; Basu, S.; Cheeseman, J.; Fielding, B.A.; Humphreys, S.M.; Danoff, T.; Moore, N.R.; Murgatroyd, P.; O'Rahilly, S.; Sutton, P.; Willson, T.; Hassall, D.; Frayn, K.N. and Karpe, F. (2008) Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes, 57, 332-339.
121. Shin, H.D.; Park, B.L.; Kim, L.H.; Jung, H.S.; Cho, Y.M.; Moon, M.K.; Park, Y.J.; Lee, H.K. and Park, K.S. (2004) Genetic polymorphisms in peroxisome proliferator-activated receptor delta associated with obesity. Diabetes, 53, 847-851.